GlassScriptPhysician profile
Scott Sagett
NPI 1609811967
$1,447.47
in general payments reported to CMS, 2019-2025
19 companies · $445 in 2025
The $445 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $65.46 · 2021: $244 · 2022: $226 · 2023: $190 · 2024: $160 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $472.67 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $211.75 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $161.21 | 2025 | Xdemvy |
| Alcon Vision LLC | $136.69 | 2022-2025 | Clareon, Tryptyr, Eysuvis |
| Aerie Pharmaceuticals, INC. | $85.55 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $57.32 | 2021-2025 | |
| Bausch & Lomb Americas INC. | $47.48 | 2023-2024 | Miebo, Xiidra, Vyzulta |
| Thea Pharma INC. | $38.04 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $32.69 | 2020 | |
| Harrow Eye, LLC | $28.60 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $26.80 | 2022 | |
| Lumenis, INC | $23.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.37 | 2023 | |
| Omeros Corporation | $19.70 | 2019 | |
| Kala Pharmaceuticals, INC. | $18.23 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $18.05 | 2020 | |
| Eyevance Pharmaceuticals LLC | $17.60 | 2022 | |
| Rxsight INC | $15.44 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Injector Cartridge |
| Shire North American Group INC | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Sagett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.